



PATENT  
18810-81552

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of: Daniel H. Cohn, Muhammad Faiyaz ul Haque, Lily M. King and  
Deborah Krakow  
Serial No. 09/898,165  
Filed: July 2, 2001  
For: 3-PHOSPHOADENOSINE-5-PHOSPHOSULFATE (PAPS)  
SYNTHETASE PROTEINS AND METHODS FOR TREATING  
OSTEOARTHRITIC DISORDERS

Examiner: Saidha, Tekchand

Unit: 1652

**DECLARATION UNDER 37 C.F.R. § 1.821 (f) (g)**

**CERTIFICATE OF MAILING BY U.S. POSTAL SERVICE FIRST CLASS MAIL**

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE POST OFFICE FOR MAILING TO ADDRESSEE\* BY FIRST CLASS POSTAL SERVICE UNDER 37 CFR 1.8 ON THE DATE AND LABEL INDICATED BELOW AND IS ADDRESSED TO BOX SEQUENCE, THE ASSISTANT COMMISSIONER FOR PATENTS, P.O. BOX 2327, ARLINGTON, VA 22202--

**February 27, 2003**

Date of Deposit and Signature

Raun Burnham

**BOX SEQUENCE**

Assistant Commissioner for Patents, P.O. Box 2327  
Arlington, Virginia 22202

Dear Sir:

I, Nisan A. Steinberg, Ph.D., hereby state, as required by 37 C.F.R. § 1.821(f), that the content of the paper and computer readable copies of the enclosed sequence listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are to the best of my knowledge, the same, and are the same as the sequences disclosed in a Response to Office Communication and Preliminary Amendment, which Applicant mailed October 24, 2002. To the best of my knowledge, they contain sequences that are the same as the sequences disclosed in the application as originally filed.

I hereby also state, as required by 37 C.F.R. § 1.821(g), that to the best of my knowledge, the enclosed submission includes no new matter.

Respectfully submitted,

By:

Nisan A. Steinberg, Ph.D.  
Registration No. 40,345

SIDLEY AUSTIN BROWN & WOOD  
555 West Fifth Street  
Los Angeles, California 90013-1010  
Ofc: 213/ 896-6665  
Fax: 213/896-6600

**RECEIVED**


MAR 07 2003

TECH CENTER 1600/2900

Application No.: 09/895165

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: Applicant should follow the format of the attached sample statement to request that the CRF filed in the parent application be used to create a CRF in this application.

**Applicant Must Provide:**

- ☒ An Initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An Initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patent/In software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

**RECEIVED**  
MAR 07 2003  
TECH CENTER 1600/2900